|
Compounds/Agents in Clinical trials | Tumor type | Identifier |
|
A Phase II trial of dasatinib | Advanced sarcoma | SARC009 |
A Phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor | Recurrent or refractory ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, and other sarcomas | SARC011 |
A randomized, double-blinded, placebo-controlled, multiinstitutional, phase II.5 study of AZD0530, a selective Src kinase inhibitor | Recurrent osteosarcoma localized to the lung | SARC012 |
IMC-A12 and doxorubicin hydrochloride | Patients with unresectable, locally advanced, or metastatic soft tissue sarcoma | NCT00720174 |
IMC-A12 | Young patients with relapsed or refractory ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumor | NCT00609141 |
R1507 | Patients with recurrent or refractory sarcoma | NCT00642941 |
CP751871 figitumumab combined with pegvisomant | Advanced solid tumors | NCT00976508 |
Bevacizumab and AZD2171 | Patients with metastatic or unresectable solid tumor, lymphoma, intracranial glioblastoma, gliosarcoma, or anaplastic astrocytoma | NCT00458731 |
Cediranib (tentative trade name recentin), also known as AZD2171 | Young patients with refractory or recurrent solid tumors or acute myeloid leukemia | NCT00354848 |
Temozolomide, cixutumumab, and combination chemotherapy | Treating patients with metastatic rhabdomyosarcoma | NCT01055314 |
Cixutumumab IMC A12 | Treating patients with relapsed or refractory solid tumors | NCT00831844 |
Cixutumumab and temsirolimus | Treating young patients with solid tumors that have recurred or not responded to treatment | NCT00880282 |
A study of SCH 717454 in combination with different treatment regimens | Pediatric subjects with advanced solid tumors (Study P05883) | NCT00960063 |
SCH 717454 in combination with different treatment regimens | Advanced solid tumors (P04722) | NCT00954512 |
Temsirolimus and valproic acid | Treating young patients with relapsed neuroblastoma, bone sarcoma, or soft tissue sarcoma | NCT01204450 |
Temsirolimus, irinotecan hydrochloride, and temozolomide | Treating young patients with relapsed or refractory solid tumors | NCT01141244 |
PCI-24781 in combination with doxorubicin | Treat sarcoma | NCT01027910 |
Angiogenesis inhibitor SU5416 | Treating patients with soft tissue sarcoma | NCT00023738 |
Sorafenib and bevacizumab | Treating patients with refractory, metastatic, or unresectable solid tumors | NCT00098592 |
Sunitinib | Treating patients with metastatic, locally advanced, or locally recurrent sarcomas | NCT00474994 |
Radiation therapy with or without SU5416 (TK inhibitor antiangiogenesis compound) | Treating patients with soft tissue sarcoma | NCT00023725 |
Phase II study of doxorubicin and bevacizumab (anti-VEFG monoclonal antibody, NSC 704865) | Patients with advanced or metastatic soft-tissue sarcoma | NCT00052390 |
Phase I/II study of gemcitabine, docetaxel, and bevacizumab | Patients with soft tissue sarcoma | NCT00276055 |
Phase II study of neoadjuvant bevacizumab and radiation therapy | Resectable soft tissue sarcomas | NCT00356031 |
|